US · RLAY
Relay Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- relaytx.com
Price · as of 2025-12-31
$12.72
Market cap 1.78B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.73 | +125.86% |
| Intrinsic Value(DCF) | $3.93 | -69.1% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $39.29 | $6.02 | $5.57 | ||
| 2021 | $23.70 | $34.11 | $5.01 | $0.00 | $321.58 |
| 2022 | $15.33 | $28.27 | $5.29 | $0.00 | $113.64 |
| 2023 | $10.32 | $234.89 | $2.31 | $0.00 | $0.00 |
| 2024 | $3.46 | $24.95 | $2.42 | $0.00 | $118.25 |
| 2025 | $9.79 | $28.73 | $0.02 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Relay Therapeutics, Inc.'s (RLAY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.73
- Current price
- $12.72
- AI upside
- +125.86%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.93
-69.1% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RLAY | Relay Therapeutics, Inc. | $12.72 | 1.78B | +126% | -69% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| AMLX | Amylyx Pharmaceuticals, I… | $15.17 | 1.26B | +1,990% | -90% | — | +1,813% | -0.87 | 1.60 | 3.02 | -0.31 | — | 1.60 | 51.75% | -360.22% | -345.36% | -100.88% | -1111.62% | -84.87% | 0.01 | — | 6.67 | 6.23 | 0.26 | -73286.00% | -7706.00% | -167149.00% | -63.63% | -5.90 | -593.45% | 0.00% | 0.00% | 0.00% | -0.28 | -0.53 | 1.02 | -2.82 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| INBX | Inhibrx Biosciences, Inc. | $74.13 | 1.08B | +370% | -93% | +699% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| ORIC | ORIC Pharmaceuticals, Inc… | $13.45 | 1.31B | — | — | — | — | -9.41 | 3.17 | — | -7.40 | — | 3.17 | 0.00% | — | — | -41.27% | -272.98% | -37.79% | 0.03 | — | 14.13 | 13.79 | 0.27 | -1967.00% | — | 20.00% | -9.36% | -5.55 | -217.77% | 0.00% | 0.00% | 0.00% | -6.63 | -8.32 | — | 24.72 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| ZBIO | Zenas BioPharma, Inc. | $26.35 | 1.1B | -12% | -81% | — | +1,012% | -1.98 | 1.00 | 62.26 | 0.23 | -0.69 | 1.00 | -2682.78% | -3277.76% | -3139.76% | -361.99% | 109.71% | -71.66% | 0.00 | — | 6.21 | 6.12 | 1.95 | 28763.00% | -9000.00% | 29221.00% | -38.49% | -2.09 | 80.20% | 0.00% | 0.00% | 90.91% | 0.23 | 0.32 | -7.69 | 1.30 |
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- CEO
- Sanjiv K. Patel
- Employees
- 259
- Beta
- 1.62
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.93 ÷ $12.72) − 1 = -69.1% (DCF, example).